The combination of encorafenib and binimetinib (Braftovi and Mektovi) has been granted approval by the U.S. Food and Drug Administration
Regulatory
FDA Approves Drug Duo for BRAF-Positive Melanoma
The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma
The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi)
Dabrafenib/Trametinib Combination Approved in BRAF-Mutant Melanoma
The US Food and Drug Administration (FDA) granted approval to the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the adjuvant treatment of melanoma.